Skip to main content
. 2021 May 20;24(5):338–344. [Article in Chinese] doi: 10.3779/j.issn.1009-3419.2021.104.06

表 2.

不同EGFR突变的患者接受免疫联合治疗的近期疗效

Short-term efficacy of combined immunotherapy in patients with different EGFR mutations

Response 19del L858R Combined with T790M Other mutation
CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; ORR: objective response rate; DCR: disease control rate.
CR 0 0 0 0
PR 4 5 1 1
SD 2 2 4 3
PD 0 1 3 1
Total 6 8 8 5
ORR 66.67% 62.50% 12.50% 20.00%
DCR 100.00% 87.50% 62.50% 80.00%